Negative correlation between Placental Growth Factor and Endocan-1 in women with preeclampsia by Hentchke, Marta Ribiero et al.
Negative Correlation between Placental Growth Factor
and Endocan-1 in Women with Preeclampsia
Correlação negativa entre fator de crescimento
placentário e endocan-1 emmulheres com pré-eclâmpsia
Marta Ribeiro Hentschke1 Edson Vieira da Cunha Filho1 Matias Costa Vieira1 Letícia Germany Paula1
Hiten D. Mistry2 Bartira Ercília Pinheiro da Costa1 Carlos Eduardo Poli-de-Figueiredo1
1LaboratoryofNephrology,Hospital São Lucas, School ofMedicine, Pontifícia
Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
2Division of Child Health, Obstetrics & Gynecology, University of
Nottingham, Nottingham, United Kingdom
Rev Bras Ginecol Obstet 2018;40:593–598.
Address for correspondence Marta Ribeiro Hentschke, MD, PhD,
Laboratório de Nefrologia, Hospital São Lucas, Escola de Medicina,
Pontifícia Universidade Católica do Rio Grande do Sul, Av. Ipiranga
6.690, 90610-000, Porto Alegre, RS, Brazil
(e-mail: martarh@yahoo.com.br; martahentschke@gmail.com).
Keywords
► pregnancy-induced
hypertension
► preeclampsia
► endothelial function
► biomarkers
► cytokines
Abstract Objective To analyze endocan-1, a biomarker of vascular endothelial related pathol-
ogies, and the placental growth factor (PlGF), an angiogenic factor and a placental
dysfunction marker in patients with preeclampsia (PE).
Methods Case-control study conducted at Hospital São Lucas, in the city of Porto
Alegre, Brazil. Endocan-1 and PlGF levels were quantiﬁed in the maternal plasma using
the MagPlexTH-C microsphere system (MAGPIX System, Luminex, Austin, Texas, US)
and evaluated through analysis of covariance (ANCOVA) and adjusted by body mass
index (BMI), gestational age and maternal age. To estimate the difference between the
groups, the mean ratio (MR) and the 95% conﬁdence interval (95%CI) were calculated.
The Pearson correlation test was used to establish any association between endocan-1
and PlGF levels. The null hypothesis was rejected when p < 0.05.
Results The group of patients was composed by normotensive (n ¼ 67) patients and
patients with PE (n ¼ 50). A negative correlation between endocan-1 and the PlGF was
noted in the entire normotensive group (linear correlation coefﬁcient [r] ¼ 0.605;
p < 0.001), as well as in the PE group (r ¼ 0.545; p < 0.001).
Conclusion Endocan-1 levels are increased in patients with PE, and are inversely
correlated with PlGF levels. We suggest that it is important to analyze angiogenic and
proinﬂammatory molecules concomitantly in women with PE to better understand the
pathophysiology of the disease. Both molecules are strong candidates for PE biomarkers,
and future studies will examine any mechanisms connecting these factors in PE.
Resumo Objetivo Analisar o endocan-1, um biomarcador de patologias vasculares endoteliais,
e o fator de crescimento placentário (FCPl), um fator angiogênico, marcador de
disfunção placentária em pacientes com pré-eclâmpsia (PE).
Métodos Estudo de caso-controle realizado no Hospital São Lucas, em Porto Alegre.
Os níveis de endocan-1 e FCPl foram quantiﬁcados no plasma materno usando o
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Introduction
Preeclampsia (PE) is one of the 3 major causes of maternal
morbidity and mortality in the world, affecting 2 to 8% of all
pregnancies.1 The etiology of PE remains unknown, but it is
thought to begin inplacentation,when there is an impairment
in the vascular remodeling of the uterine spiral arteries that
leads to a decrease in perfusion and high uteroplacental
resistance, creatinganenvironmentofhypoxia to theplacental
and fetal tissues. Placental hypoxia results in the release of
cytokines that, when exposed to the maternal circulation,
change the vascular response, leading to widespread dysfunc-
tion of the maternal endothelium.2–7
Identifying a patient with PE is one of the major goals of
prenatal care, so the patient can be referred to high-risk
pregnancy protocols, with speciﬁc treatment, and, if neces-
sary, plan the termination of the pregnancy.8
The endocan-1molecule is a soluble proteoglycan expressed
speciﬁcally in endothelial cells. This molecule has been studied
in experimental models as well as in vivo, and studies have
shown that it is a possible marker and predictor of many
diseases9–11 associated with the vascular endothelium.9,12–21
Therefore, endocan-1 appears to play a key role in tumor
progressionand intheregulationof the inﬂammatoryprocess.22
Regarding the association of endocan-1with PE, our group
recently published a study that demonstrated a signiﬁcant
increase in endocan-1 levels in the maternal plasma of
women with preeclampsia;23 subsequently, Chang et al.24
demonstrated the same association in the placental tissue,
and Cakmak et al25 associated higher serum endocan con-
centrations with the severity of the disease.
A molecule that has been widely associated with the
pathophysiology of diseases is the placental growth factor
(PlGF). It is produced by the placenta, and has an angiogenic
action. During pregnancy, the PlGF is considered a marker of
placental dysfunction. Plasma concentrations of PlGF are
down-regulated in patients with PE and intrauterine growth
restriction (IUGR), and PlGF has been studied as a biomarker
and risk predictor for the development of PE.6,26,27
In order to predict the chances of developing preeclamp-
sia, it is important to associate molecules that are related
both to cell growth and inﬂammatory cytokines, two key
points of PE patients. We hypothesized that there would be a
negative correlation between endocan-1 and the PlGF. Thus,
the objective of the present study was to correlate the levels
of endocan-1 and PlGF in the plasma of pregnant women
with and without PE.
Methods
An observational, case-control study that included pregnant
women with a single fetus and with or without diagnosis of
PE, who were hospitalized in Hospital São Lucas, Pontífícia
Universidade Católica do Rio Grande do Sul (HSL/PUCRS, in
the Portuguese acronym), in the city of Porto Alegre, Brazil,
between 2010 and 2013. All samples were collected after
obtaining informedwritten consent. The studywas approved
by the institution’s Scientiﬁc and Ethics in Research Com-
mittee (under no. 11/05352-CEP). Preeclampsia was deﬁned
according to the National High Blood Pressure Education
Program28 and to the VI Brazilian Hypertension Guidelines29
as blood pressure  140/90 mm Hg, associated with patho-
logical proteinuria  300 mg/24 hours or a proteinuria/
creatininuria ratio  0.3, after 20 weeks of gestation. Early
onset PE was considered when the PE developed with
gestational age (GA) < 34 weeks. The sample was divided
into two groups: one group composed of normotensive
(NT) patients, and another group composed of patients
with PE. The PE groupwas called “PE pure” after the pregnant
women with superimposed PE and hemolysis, elevated
liver enzymes, low platelet count (HELLP ) syndrome were
excluded from the analysis.
sistema de microesferas MagPlexTH-C (MAGPIX System, Luminex, Austin, Texas, US) e
analisados por análise de covariância (ANCOVA) e ajustados por índice de massa
corporal (IMC), idade gestacional e idade materna. Para calcular a diferença entre os
grupos, utilizou-se a razão dasmédias (RM) e o intervalo de conﬁança de 95% (IC95%). O
teste de correlação de Pearson foi utilizado para estabelecer a associação entre os
níveis de endocan-1 e FCPl. A hipótese nula foi rejeitada quando p < 0,05.
Resultados O grupo de pacientes foi composto por pacientes normotensas (n ¼ 67)
e pacientes com PE (n ¼ 50). Uma correlação negativa entre o endocan-1 e o FCPl foi
observada em todo o grupo de pacientes normotensas (coeﬁciente de correlação linear
[r] ¼ 0,605; p < 0,001), bem como no grupo com PE (r ¼ 0,545; p < 0,001).
Conclusão Os níveis de endocan-1 estão aumentados em pacientes com PE e
inversamente correlacionados com os níveis de FCPl. Sugerimos a importância de
analisar moléculas angiogênicas e pró-inﬂamatórias concomitantemente em mulheres
com PE para compreender melhor a ﬁsiopatologia da doença. Ambas as moléculas são
fortes candidatos a serem considerados biomarcadores de PE, e trabalhos futuros
poderão avaliar quaisquer mecanismos que liguem esses fatores na PE.
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Data from the maternal identiﬁcation, the physical exami-
nation (upon hospital admission), the previous medical histo-
ry, the maternal family history, the laboratory tests, the
delivery, and the newborn were recorded. For both groups,
women were excluded had they had a previous diagnosis of
kidney disease, liver disease, active infection, multiple gesta-
tion, and/or if there was lack of information in the database.
Sample Collection
Maternal blood collectionwas performed after diagnosis (for
the PE group) and hospitalization for delivery (for the NT
group), in the third trimester of pregnancy. The ﬁnal sample
was composed of 117 patients (50 with PE and 67 NTs).
Before delivery, 4 ml of maternal blood were collected in
ethylenediaminetetraacetic (EDTA) acid tubes. The samples
were processed in the Nephrology Laboratory at HSL/PUCRS,
and centrifuged at 2,000 g for 10 minutes, stored in 600 μl
aliquots ﬁrst, at -20°C and then at -80°C until the time of
analysis. Laboratory exams to evaluate the severity of the PE
were conducted in the PE group.
Sample Preparation
The samples were prepared according to the instructions of
the Milliplex assay kit – MagPlexTH-C assay supplier. To
calculate the concentration of molecules, the MagPlexTH-
System C – microsphere assay (MAGPIX System, Luminex,
Austin, Texas, US), theMilliplex kits HADK2MAG-61K-05 and
HCVD1MAG-67K-02 (Millipore Corporation, Billerica, MA,
US), and the xPONENT software (Luminex), version 4.2 were
used. The intra-assay and inter-assay coefﬁcient of variation
was < 10%. The linear correlation coefﬁcient (r) of the stan-
dard curve of endocan-1, according to the Luminex instru-
ment, was r ¼ 0.98, and for the PlGF, it was r ¼ 0.99.
Statistical Analysis
Statistical testswereconductedusing theStatisticalPackagefor
the Social Sciences (SPSS, IBM Corp. Armonk, NY, US), version
19 for Windows, the Graphpad Prism 6 (GraphPad Software,
Inc., SanDiego, CA, US) and theWINPEPI (PEPI-for-Windows,©
J.H. Abramson, School of Public Health and Community Medi-
cine, Hebrew University, Jerusalem, Israel). The quantitative
variables were presented as mean  standard deviation (SD)
ormedian and interquartile range (IQR) as appropriate, and the
Mann-Whitney U-test and the Student t-test were used
depending on the data distribution. For the categorical varia-
bles, we used percentages and applied the Chi-squared test or
the Fisher exact test. Correlations between parameters were
testedwith thePearsoncorrelation coefﬁcient. Thedata related
to the levels of endocan-1 and PlGF were analyzed by logarith-
mic transformation by analysis of covariance (ANCOVA) adjust-
ed for bodymass index (BMI), GA, andmaternal age (presented
as a geometric mean). In order to estimate the proportional
difference of cytokines between the groups, the mean ratio
(MR) and 95% conﬁdence interval (95%CI) were calculated. The
magnitude of difference was estimated using the effect size
(Cohen d). The null hypothesis was rejected when p < 0.05.
Results
Study Subjects
The clinical and demographic characteristics, data from the
physical examination, the laboratory tests and data collected
at the time of delivery are presented in ►Table 1. The data
from the physical examination were collected on the day of
admission at HSL/PUCRS.
For the clinical data, we opted to use the GA at delivery
data to consider the same period of time for both groups. At
the moment of the diagnosis of PE, 21 patients were preterm
(10 with GA < 34 weeks) and 20 patients were diagnosed
with severe PE due to systolic blood pressure  160 mm Hg
and/or diastolic blood pressure  110 mm Hg.
Analysis of the Studied Molecules
The mean levels of PlGF in the NT and PE pure patients were
58.4 pg/mL and 33.05 pg/mL respectively, and the mean
Table 1 Sociodemographic data and maternal and perinatal
outcomes from the NT and PE groups
Parameters NT (n ¼ 67) PE (n ¼ 50) p-value
Maternal age, years 26  5 26  6.8 0.10
White, n (%) 34 (52) 31 (65) 0.25
Primiparous, n (%) 28 (42) 25 (51) 0.35
Chronic
hypertension, n (%)
0 (0) 12 (24.5) 
Previous PE, n (%) 1 (1.5) 12 (24.0) 
BMI, kg/m2
(weight at end of
the pregnancy)
30.4  5.8 32.3  5.4 0.081
SBP, mmHg 119  10 157  17 < 0.001
DBP, mmHg 75  8 101  14 < 0.001
GA at delivery,
weeks
39.6  1.4 36.7  3.7 < 0.001
Cesarean section,
n (%)
22 (32.8) 38 (76.0) < 0.001
5-minute Apgar, n 9.4  0.6 8.72  1.21 < 0.001
Birth weight, Kg 3,393  458 2,789  904 < 0.001
Placental
weight, Kg
649  142 590  179 0.063
Hematocrit, % 35.2  2.5 36.22  3.51 0.14
Hemoglobin, g/dL 11.6  0.9 12.31  1.28 0.004
Platelets, mm3 (mil) 211.00  59.05 
Creatinine, mg/dL 0.81  0.21 
Proteinuria,
P/C rate
0.67 [0.42;2.2] 
Fasting glucose,
mg/dL
75.2  9.3 78.9  13.7 0.26
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure (at
admission); GA, gestational age; NT, normotensive pregnancy; P/C, pro-
teinuria/creatininuria; PE, preeclampsia; SBP, systolic blood pressure.
Notes: Data are presented as mean  SD (Student t-test), or absolute
numbers and percentages (Fisher exact test), as appropriate. p < 0.05
for the NT and PE groups. In the control group, in the ﬁfth minute, no
newborn had Apgar index< 7 and in the PE group, 2 newborns received
Apgar index < 7.
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levels of endocan-1 were 2032.6 pg/mL and 3357.8 pg/mL
respectively. For the statistical analysis, the logarithmic
transformation was made, and the ANCOVA was applied.
Lower levels of PlGF were found in the PE pure group (MR
¼ 0.38; 95%CI: 0.15–0.95; p ¼ 0.041), (Cohen d ¼ 0.54) in
the maternal plasma in the PE pure group (MR ¼ 1.56; 95%
CI: 1.22 - 2,01; p ¼ 0.001) with a moderate effect size.
When the PE groupwas divided into early PE (< 34 weeks
of GA;  34 weeks of GA and controls), we found in the early
PE group lower levels of PlGF (p ¼ 0.009) and higher levels of
endocan-1 (p < 0.001).
Finally, a negative correlation between endocan-1 and the
PlGF was noted in the entire NT group (r ¼ -0,605; p < 0.001)
and in the PE group (r ¼ –0,545; p < 0.001) (►Fig. 1).
Discussion
When compared with the control group, the PlGF was  60%
lower in PE pure patients. In contrast, the level of endocan-1
between the 2 groups was 56% higher in PE pure patients,
and a strong negative correlation between the 2 molecules
was observed. In the molecular analysis, the early PE group
presented a statistically lower level of PlGFand higher level of
endocan-1. This could suggest that both molecules may be
biomarkers of early onset PE.
Many factors that may be related to PE have been pro-
posed, but the most prominent have been associated with
protein receptors of the vascular endothelial growth factor
(VEGF) family, particularly the soluble vascular endothelial
growth factor receptor-1(sVEGFR1) and the PlGF.30,31
The circulating PlGF in human beings is predominantly
PlGF-1 (currently there are PlGFs 1 to 4), which is mainly
produced by the placenta, and is signiﬁcantly reduced in
cases of PE,32,33 due to a negative regulation that occurs
under hypoxia,34 even before the onset of the PE symp-
toms.30 However, the role of the PlGF in the pathogenesis
of PE is not entirely known, partly because its physiologic
action is not fully understood. In 2008, however, Osol et al35
demonstrated that PlGF-1 is a potent vasodilator, particular-
ly regarding the uterine arteries, and ismediated specially by
the release of nitric oxide in pregnancy, which could also
regulate the venous tone. In the presence of higher levels of
sVEGFR-1, the PlGF is down-regulated, which could diminish
the vasodilation process and lead to hypertension, which is
observed in patients with PE.35
Since the early stages of pregnancy, cell injury occurs in the
extracellular matrix and in the vessel walls of the maternal
decidua to create a propitious environment for embryo im-
plantation. Ischemic lesions in the placenta resulting from
poor remodeling of the decidual vessels release molecular
mediators in the maternal circulation, creating an imbalance
between vasoconstrictors and vasodilators, culminating in PE
syndromewith aprogressing systemic response.However, it is
thought that in normal pregnancies the syncytiotrophoblast
self-renews, leaving apoptotic debris in the maternal circula-
tion, which leads to an expected inﬂammatory response
during placental growth.
The signiﬁcant increase in the concentration of endocan-1
observed in the maternal plasma might be due to this intense
response to this process of physiological development, togeth-
er with the increased release of proinﬂammatory cytokines
already observed in previous studies.7
We questioned which molecule(s) would be mediating
the inverse correlation found between the PlGFand endocan-
1, and which one seems to change ﬁrst in the pathophysiol-
ogy of the disease. There is a lack of studies trying to answer
this question clearly. It is known that studies that evaluated
both molecules in the ﬁrst trimester of pregnancy, in sepa-
rate, showed that both endocan-1 and the PlGF are decreased
in patients who developed PE.36 Findings from our group
demonstrated that the PlGF remains down-regulated, but
endocan-1 tends to increase throughout gestation. This
occurs, in part, due to the ischemia that begins and com-
promises the maternal circulation.
All of the patients in our study were included in the third
trimester of gestation, and the level of cytokines was
Fig. 1 Correlation between endocan-1 and the placental growth factor (PlGF). (A) Correlation between endocan-1 and the PlGF in the entire
group; (B) correlation between endocan-1 and the PlGF in the PE group.
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adjusted for GA to minimize the inﬂuence of this confound-
ing factor in the results.
The placenta plays a crucial role in fetal nutrition. Endocan-
1, a cytokine of predominantly inﬂammatory nature, injures
the vasculature, and, therefore, contributes to the reduction in
placental ﬂow, IUGR, and to low placental weight.
To our knowledge, there are no complete articles in the
literature that correlate these two molecules in PE.
Therefore, the study contributed to previous ﬁndings by
demonstratingdecreased PlGFand increased endocan-1 in the
third trimester of pregnancy in PE and its importance in cases
of early onset PE. We believe that, in addition to the PlGF, a
promising molecule in studies involving PE, endocan-1 also
seems to play a role in the PE pathogenesis, and may have a
relation with some clinical ﬁndings of the disease, but future
researches should be performed to clarify these hypotheses.
Conclusion
The present study evaluated the presence of endocan-1 and
PlGFmolecules in thematernal plasma; it also correlated the
levels of these cytokines in patients with PE and NT patients.
In patients with PE, endocan-1 was signiﬁcantly increased,
and the PlGF decreased in the maternal plasma. The role of
these cytokines in the pathophysiology of PE needs to be
continuously studied.
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